Insulin resistance and the polycystic ovary syndrome: Recent advances

Current Opinion in Endocrinology and Diabetes

Volumn 7, Issue 6, 2000, Pages 345-349

  Nestler, J E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DEXTRO INOSITOL; INOSITOL DERIVATIVE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; TROGLITAZONE; UNCLASSIFIED DRUG;

ADOLESCENCE; ADRENARCHE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FETUS WASTAGE; GENETIC DISORDER; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PRECOCIOUS PUBERTY; REVIEW; SYNDROME X;

EID: 0033668103     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200012000-00009     Document Type: Review

References (63)

1. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain
2. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study
3. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome
4. A twin study of polycystic ovary syndrome
5. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome
6. The importance of diagnosing the polycystic ovary syndrome
7. Insulin resistance in polycystic ovary syndrome: Treating a phenotype without a genotype
8. Role of hyperinsulinemia in the pathogenesis of the polycysticovary syndrome, and its clinical implications
9. Polycystic ovary syndrome: A disorder for the generalist
10. The polycystic ovary syndrome: Treatment with insulin sensitizing agents
11. The insulin-related ovarian regulatory system in health and disease
12. Molecular mysteries of polycystic ovary syndrome
13. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome
14. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome
15. Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome
16. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6 month trial, followed by open, long-term clinical evaluation
17. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome
18. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome
19. Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea
20. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome
21. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome
22. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
23. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome
24. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17a activity and serum androgens
25. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome
26. Decreases in ovarian cytochrome P450c17a activity and serum free testosterone after reduction in insulin secretion in women with polycystic ovary syndrome
27. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
28. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome
29. Can metformin reduce insulin resistance in polycystic ovary syndrome?
30. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome
31. High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome
32. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
33. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
34. Lean women with the polycystic ovary syndrome: D-chiroinositol reduces serum insulin and androgens, improves ovulation, and beneficially affects syndrome X by decreasing blood pressure and serum triglycerides
35. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome
36. Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia
37. Insulin resistance in nonobese patients with polycystic ovarian disease
38. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
39. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial
40. Insulin-signaling mechanisms: Lessons from the old testament of glycogen metabolism and the new testament of molecular biology
41. Second messengers of insulin action
42. Pyruvate dehydrogenase activation in adipocyte mitochondria by an insulin-generated mediator from muscle
43. Generation by insulin of a chemical mediator that controls protein phosphorylation and dephosphoylation
44. Duality in the mechanism of action of insulin
45. Chiro-inositol deficiency and insulin resistance
46. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity
47. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: Influence of insulin and genetic factors
48. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome
49. Thirty-seven candidate genes for polycystic ovary syndrome: Strongest evidence for linkage is with follistatin
50. Increased prevalence of type 2 diabetes mellitus and impaired glucose tolerance in first-degree relatives of girls with a history of precocious pubarche
51. Ovarian responses to hCG stimulation: Insulin resistance/hyperinsulinaemia vs. insulin deficiency
52. Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: From a complex constellation to a simple sequence of prenatal onset
53. Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: Evidence from gonadotropin-releasing hormone agonist testing
54. Androgens in adrenarche and pubarche
55. Premature adrenarche: Findings in prepubertal African-American and Caribbean-Hispanic girls
56. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin
57. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome
58. Hypersecretion of luteinising hormone, infertility, and miscarriage
59. Recurrent early miscarriage and polycystic ovaries
60. Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage
61. Obesity is a risk factor for early pregnancy loss after IVF or ICSI
62. Plasminogen activator inhibitor activity: An independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome
63. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome